Solta Medical

Company Overview

Solta Medical is headquartered in Bothell, WA and was founded in 1996, which means the company has been building medical devices for 30 years. The company operates in 75+ and is publicly traded under ticker BHC. Standalone annual revenue is not separately reported (Part of Bausch Health ($4.5B+)). Aesthetic division of Bausch Health Companies. Makes the Thermage monopolar RF skin tightening platform, Fraxel fractional lasers, Clear + Brilliant non-ablative laser, and VASER ultrasonic lipo. Thermage FLX is the category reference for single-session non-invasive skin tightening. Bausch has publicly discussed spinning off the aesthetics division for years without execution.

The company's product portfolio centers on Monopolar RF (Thermage), Fractional Laser (Fraxel), Fractional Non-Ablative Laser (Clear + Brilliant), with platforms targeting 2 device categories: skin tightening, skin resurfacing. Portfolio breadth matters for buyers because manufacturers with multiple platforms can bundle training, service contracts, and consumable agreements across devices. Single-category manufacturers typically have less negotiating flexibility, though they can offer deeper expertise in their specific domain. When evaluating Solta Medical, the right question is not whether the portfolio is wide or narrow, but whether the specific platform you need is strategically important to the company or a legacy product being phased out.

Manufacturer financial stability is a real consideration for capital equipment buyers. Solta Medical's public market visibility means quarterly financials, analyst coverage, and SEC-filed risk factors are all accessible. For physicians considering a Solta Medical platform, the questions worth asking are warranty term length, parts availability commitments, software update policy, and service response times in your specific region. Manufacturers in financial distress sometimes cut these obligations first, and they rarely announce it publicly. The strongest signal of real manufacturer health is whether they are investing in new product development, acquiring complementary technology, or coasting on existing revenue.

Technology Platform

Solta Medical's core technology stack includes Monopolar RF (Thermage), Fractional Laser (Fraxel), Fractional Non-Ablative Laser (Clear + Brilliant). Each platform represents distinct R&D investment and targets specific clinical indications. Physicians evaluating Solta Medical devices should understand which technology drives which platform because the mechanism of action varies across the company's product lineup.

The technology portfolio is deeper than a single-platform manufacturer, which matters for practices that want to consolidate device purchases with one vendor for training, service, and consumable efficiency. Platform breadth also signals R&D commitment, though it can stretch engineering and support resources thin when the company expands into too many categories at once.

• Monopolar RF (Thermage)
• Fractional Laser (Fraxel)
• Fractional Non-Ablative Laser (Clear + Brilliant)

Product Lineup

Solta Medical currently produces the devices listed below across 2 categories. Each device links to a full independent review with pricing, clinical evidence, pros and cons, and comparisons against category alternatives.

Market Position

Solta Medical competes across 2 device categories, which positions the company differently in each market segment. In some categories, Solta Medical leads on installed base and brand recognition. In others, the company is the value alternative or the technology challenger. Buyers should evaluate the company category by category rather than treating it as uniformly strong or weak across its entire portfolio.

The competitive set varies by category. In skin tightening, Solta Medical faces a different competitive landscape than in any other segment. Some categories are dominated by 2-3 incumbents. Others are fragmenting as new entrants push on price or differentiate on clinical evidence. For physicians evaluating Solta Medical platforms, the right question is not whether the company is good or bad in general, but how well its specific platform stacks up against the named competitors in your category of interest.

Strengths and Weaknesses

Solta Medical's strengths typically include manufacturer scale, international presence (75+), and a publicly traded structure. Companies with this profile usually have stronger sales infrastructure, better training programs, and more predictable parts and service support than smaller competitors. The technology portfolio (Monopolar RF (Thermage), Fractional Laser (Fraxel)) represents real R&D investment that smaller players can't match.

Weaknesses to weigh: any large manufacturer faces pricing pressure from value-tier competitors, distribution challenges in regions where dealer networks are thin, and the constant risk that a clinical safety signal in one product affects perception of the entire portfolio. Physicians evaluating Solta Medical should look at the specific platform they're considering rather than the parent brand. A strong manufacturer can have weak platforms in specific categories, and a struggling manufacturer can have category-leading products. Brand-level reputation is a starting point, not a substitute for platform-level diligence.

Who Should Consider Solta Medical

Solta Medical fits best for practices that value public market visibility and analyst-tracked financials, want access to platforms across 2 categories, and benefit from international support infrastructure. Practices that prioritize bundled training, multi-device service contracts, or trade-in programs across a manufacturer's portfolio also benefit from larger players like Solta Medical.

The fit is weaker for practices that prioritize the absolute lowest price, want to work with smaller manufacturers that offer more personalized service, or need niche features that only specialist competitors provide. The right manufacturer depends on what your practice values more than the manufacturer itself. Match the company to your priorities, not the other way around.

Risk Factors for Buyers

Every medical device purchase carries manufacturer risk. Solta Medical's risk profile reflects its size, history (30 years of operation), and structure (public ownership). Public-company transparency helps in one direction: you can read the quarterly risk factors section in their 10-K and see what management itself considers the biggest threats to the business. Quarterly earnings calls reveal whether the company is meeting analyst expectations, losing market share, or facing margin compression from competitors. Stock price movement is a noisy but useful sentiment indicator.

Specific risks to monitor before signing a purchase contract with Solta Medical: warranty coverage (duration, what is covered, and exclusions), parts and service response times in your region (not the national average), software update policy (are updates included in the maintenance contract or charged separately?), consumable pricing stability (have consumable prices increased by more than 5% annually over the past three years?), and ownership change risk (is the company rumored to be for sale, spinning off a division, or preparing for an IPO or acquisition?). Each of these questions has a real answer that a well-informed buyer can verify through conversations with existing Solta Medical customers in your region.

What to Negotiate with Solta Medical

Capital equipment sales reps have significant pricing flexibility that practice buyers rarely fully capture. The published list price on a Solta Medical platform is almost never the real transaction price. Most deals close at 10-20% below list for single-device purchases and 20-30% below list for multi-device bundles. End-of-quarter and end-of-year timing gives you a real pricing advantage because reps have quota pressure to close before their fiscal period closes. Trade-in programs for older devices can reduce net cost by another 10-20%, though the trade-in valuation is often where manufacturers claw back the discount.

Beyond price, the items worth negotiating with Solta Medical include: extended warranty coverage (ask for 24-36 months instead of the standard 12), applicator or accessory inclusions (always ask for additional applicators, treatment tips, or probes thrown in at no cost), consumable starter packages (enough consumables to cover 60-90 days of typical practice use), training and certification (ensure multiple providers in your practice can be trained without additional fees), marketing support (co-marketing funds, patient education materials, or launch campaign support), and trade-in credit for any existing devices you are replacing. An itemized quote can expose missing scope and contract risk. Compare like-for-like configurations and put every material promise in writing.

Solta Medical: Ownership, Products, and Buyer Guide

Solta Medical is the aesthetics division of Bausch Health Companies, the public company traded under ticker BHC. Its product lineup includes Thermage FLX, Fraxel, Clear + Brilliant, and VASER. For a practice buyer, that corporate structure shapes service expectations, contract terms, and the question hanging over every expensive platform purchase: who will support it over the life of the equipment?

Solta is headquartered in Bothell, Washington, and was founded in 1996. It has built its business around established aesthetic-device categories rather than chasing every new treatment trend. Thermage FLX remains its reference product for single-session, non-invasive skin tightening. Fraxel carries the resurfacing side of the portfolio. Clear + Brilliant gives practices a lighter-entry laser treatment, while VASER serves body-contouring providers.

That range can make Solta an attractive vendor for practices building a broader aesthetics menu. It can also make a bundle harder to evaluate. A package with several platforms may look efficient on a proposal while quietly tying the practice to one service organization, one training model, and one set of consumable assumptions.

Before signing, separate the company profile from the equipment decision. The products may fit your treatment mix. The commercial terms still need work.

Who Owns Solta Medical

Bausch Health owns Solta Medical. Bausch Health trades under BHC, and Solta operates as part of its aesthetics business rather than as an independent public company.

That answers the ownership question cleanly, but it does not remove the practical issue for buyers. Bausch has discussed separating its aesthetics business over time without completing a transaction. The talk matters because a spin-off can change the people responsible for field service, sales coverage, clinical education, and capital-equipment priorities.

A corporate change does not automatically make a device purchase risky. Thermage, Fraxel, Clear + Brilliant, and VASER are established platforms with existing installed bases. The risk sits in the handoff. Service processes, account ownership, trade-in programs, and commercial policies can get less predictable when a parent company rearranges a division.

Ask the salesperson a direct question: who will own service responsibility if Solta becomes part of a separate business? Get the answer in writing if the deal includes an extended service commitment. Verbal reassurance is cheap. A contract clause is the useful part.

Bausch ownership also gives buyers access to public-company disclosures. Read the company's annual filings before treating a device proposal as a standalone clinical decision. Those filings show how management describes debt, restructuring, supply exposure, and other business risks. You are not buying a ticker symbol, but you are buying equipment from an organization affected by those decisions.

For most practices, Solta's ownership structure should be one input among several. Product demand, provider utilization, local competition, financing terms, and downtime protection will determine whether the purchase earns its place in the practice.

Solta Medical Products and Platforms

Solta's portfolio covers several recognizable aesthetic categories. Each platform has a different role in a treatment menu, patient conversation, and revenue model.

Thermage FLX is the company's monopolar radiofrequency skin-tightening platform. It is widely used for patients who want a non-invasive treatment and do not want laser resurfacing, surgery, or a series-heavy treatment plan. Its single-session positioning is a big part of the appeal. It also puts more pressure on patient selection, consultation quality, and pricing discipline. A practice cannot rely on repeat-treatment volume in the same way it might with a lighter procedure.

Read the Thermage FLX device profile alongside the manufacturer proposal. The clinical story and the commercial story are related, but they are not the same document.

Fraxel is Solta's fractional laser family. Fraxel Dual is commonly evaluated by practices focused on resurfacing, pigmentation, sun damage, texture, and acne-scar treatment. It can carry a more involved operational burden than a simple skin-tightening treatment: consultation time, pre-treatment screening, post-treatment instructions, provider training, and expectations management all matter.

Clear + Brilliant sits lower on the intensity spectrum. It is a non-ablative laser platform intended for practices that want a more accessible skin-quality treatment. The appeal is obvious. Patients often understand "refresh" treatments more readily than a heavier resurfacing plan. The commercial risk is less obvious: if the practice already has multiple devices aimed at skin quality, Clear + Brilliant can become the machine everyone likes but nobody specifically books.

VASER is Solta's ultrasonic liposuction platform. It belongs in a different operational category from the company's skin devices. VASER requires the practice to think through procedural facilities, staffing, recovery protocols, physician capability, and liability exposure. Do not let a multi-device sales conversation blur that distinction. A body-contouring platform should stand on its own economics.

A Solta bundle can make sense when the practice has a defined plan for each platform. It makes less sense when a vendor has used a package discount to turn a tentative interest into a purchase order. Equipment does not become strategic because it arrives on the same invoice.

The better question is whether each platform has a clear job. Thermage may bring in skin-tightening patients. Fraxel may deepen the resurfacing offering. Clear + Brilliant may give the practice a lower-intensity entry point. VASER may expand body procedures. If two devices compete for the same patient without a distinct clinical or commercial role, one of them may spend too much time idle.

Solta Medical Revenue and Corporate Status

Solta's revenue reports inside Bausch Health, which does not break out the aesthetics division separately. There is no standalone Solta Medical revenue figure that a buyer can use as a clean measure of the division's sales, margins, or device-level performance.

That limitation is worth stating plainly because it changes what corporate research can tell you. You can evaluate Bausch Health's public disclosures, but you cannot treat company-level results as a direct read on Solta's capital-equipment business.

For a practice owner, that means the more useful operating questions are closer to the purchase itself. How quickly can the company provide service in your market? What parts are stocked? Who handles clinical training? What happens if a device is down during a scheduled treatment week? How much of the economics depend on branded consumables, tips, or accessories?

The vendor should be able to answer those questions with specifics. If it cannot, the proposal is asking you to underwrite uncertainty with capital you could spend elsewhere.

Corporate status also affects resale assumptions. Buyers sometimes assume a recognized manufacturer creates a reliable trade-in market. Recognition helps, but trade-in value depends on the model, age, service history, remaining warranty, and what the manufacturer wants to sell next. A trade-in quote should never be treated as guaranteed value until it is documented in the agreement.

The same caution applies to product roadmaps. A sales team may discuss future upgrades, software changes, or replacement paths. Ask what is included today. Ask what requires a future payment. Ask whether a promised upgrade is contractual or part of a conversation.

Flagship Device Pricing

List price gives you a starting point, not a final number. Fraxel Dual skin resurfacing lists at $95,000-$145,000, while Thermage FLX skin tightening lists at $60,000-$110,000. Device Pulse's Solta Medical profile provides those ranges.

List price is not the only cost. Service coverage, treatment tips, training, financing, shipping, installation, and expected downtime can move the actual economics far more than a modest discount on the hardware.

A proposal should show every recurring cost in plain language. Do not accept a summary that calls consumables "standard" without defining the expected use per treatment. Do not accept a warranty description that leaves out labor, travel, software, handpieces, or loaner equipment. Those exclusions are where a cheap deal becomes expensive.

If you are comparing Thermage with another skin-tightening device, use a common model. Compare expected annual treatments, revenue per treatment, provider time, consumable cost, maintenance, and patient demand. A lower purchase price can lose if it needs more treatments to create the same patient interest. A higher purchase price can lose if the practice cannot keep the schedule full.

The skin tightening category guide is useful for separating the device's clinical fit from the manufacturer's sales narrative.

How to Negotiate a Solta Medical Purchase

Most deals close at 10-20% below list for single-device purchases. Device Pulse's Solta Medical profile reports that range, which gives buyers room to ask for a better starting point without pretending every deal should look the same.

Multi-device bundles close at 20-30% below list. Device Pulse's Solta Medical profile reports that range for bundled purchases. A bundle discount can be valuable, but only if each device has a defined role and the practice would have bought it independently.

The first negotiation move is to decide whether you want the equipment, the service package, or both. Sales teams often protect hardware price while giving more ground on training, warranties, consumables, and financing. That can work in your favor. A concession in the right place may be worth more than another point off the purchase price.

Ask for extended warranty coverage of 24-36 months instead of the standard 12. Device Pulse's Solta Medical profile identifies that request as a practical negotiating point. For a capital device, downtime protection often carries more value than a cosmetic discount.

The warranty language should name what is covered. "Full coverage" is not a useful answer. Ask about labor, travel, replacement parts, software, handpieces, response times, and whether the company provides a loaner if repair takes longer than expected. A practice with booked patients does not care whether a service department considers a delay reasonable.

Trade-in offers deserve the same skepticism. Get the device being traded, its condition assumptions, the amount credited, and the conditions for receiving that credit into the agreement. If the trade-in figure depends on an inspection later, it is an estimate. Treat it that way.

Training should be part of the negotiation, especially for platforms requiring meaningful consultation, treatment planning, or procedural preparation. A device that arrives with minimal education creates a strange incentive: the manufacturer has booked the sale while the practice carries the ramp-up risk.

You can find a more detailed deal checklist in How to negotiate with Solta Medical. Use it before the proposal reaches the point where everyone is talking about delivery dates instead of terms.

What Buyers Should Ask Before Signing

Start with patient demand. Which existing patients would receive this treatment, and what is the evidence that they will pay for it? "Our competitors have one" is not enough. Competition can validate a category, but it can also mean the market has already trained patients to shop on price.

Then ask what the device replaces. If the answer is "nothing," the practice needs a clear acquisition plan. If the answer is an existing platform, compare the operational burden and patient outcomes before assuming newer means better.

Ask about service coverage in your area. The answer should include the local process, not a generic promise of support. Ask how replacement parts are handled. Ask whether service is performed by company employees, third parties, or a mixed model. Ask who coordinates the case when a device issue interrupts scheduled treatments.

Ask about financial flexibility. A vendor that wants a long relationship should be willing to discuss payment timing, early upgrade paths, and trade-in conditions. The proposal should not force the practice to accept every uncertainty while the manufacturer keeps every option.

Solta has a recognizable portfolio and a parent company with public disclosures. Those are useful advantages. They do not eliminate the ordinary discipline of a capital purchase. The winning buyer is the one who separates clinical enthusiasm from contract language before the equipment is installed.